• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …

Abstract Aim The “2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the
Management of Hypertrophic Cardiomyopathy” provides recommendations to guide …

Abstract Aim The “2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management
of Patients With Atrial Fibrillation” provides recommendations to guide clinicians in the …

In the last three decades, ablation of atrial fibrillation (AF) has become an evidence-based
safe and efficacious treatment for managing the most common cardiac arrhythmia. In 2007 …

Background: Morbidity from undiagnosed atrial fibrillation (AF) may be preventable with
early detection. Many consumer wearables contain optical photoplethysmography (PPG) …

Background It is unknown whether screening for atrial fibrillation and subsequent treatment
with anticoagulants if atrial fibrillation is detected can prevent stroke. Continuous …

The recommendations listed in this guideline are, whenever possible, evidence based. An
initial extensive evidence review, which included literature derived from research involving …

MicroRNAs (miRNAs) are small regulatory molecules post-transcriptionally suppressing
mRNA activity. Many miRNAs in various organisms have been cloned but many unknown …

Aim This executive summary of the hypertrophic cardiomyopathy clinical practice guideline
provides recommendations and algorithms for clinicians to diagnose and manage …

Abstract The Canadian Cardiovascular Society (CCS) atrial fibrillation (AF) guidelines
program was developed to aid clinicians in the management of these complex patients, as …